IRS Logo
Print - Click this link to Print this page

Qualifying Therapeutic Discovery Project Grants for the State of Utah

The listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant.

The project descriptions below were extracted from the applicant certification forms as submitted.

Utah $ 12,700,060.87
Applicant Name Project Name Grants Awarded for 2009 Grants Awarded for 2010
Aciont Inc Non-Invasive Treatment for Severe Uveitis and Related Posterior Eye Inflammation Diseases $ 101,144.50 $ 143,334.75
Aciont Inc Iontophoretic Treatment for Age-related Macular Degeneration and Diabetic Retinophathy $ 51,409.00 $ 193,070.25
Activatek Inc ActivaPatch Active Drug delivery $ 149,402.50 $ 95,076.74
Allocure Inc. Multipotent Marrow Stromal Cells for Acute Renal Failure $ 244,479.25  
BIOMERICS, LLC QUADRABAN $ 244,479.25  
Bio-Path Holdings, Inc. Phase 1 Clinical Trial of Liposomal Grb-2   $ 244,479.25
BSD Medical Corporation MTX-180 $ 244,479.25  
BSD Medical Corporation BSD-2000 Hyperthermia System $ 244,479.25  
Catheter Connections Inc DualCap for infection control during infusion therapy $ 167,500.11 $ 76,979.14
COHEREX MEDICAL INC Left Atrial Appendage ("LAA") Occlusion System $ 244,479.25  
Coherex Medical, Inc Polymer-Based Closure System for Treatment of Patent Foramen Ovale ("PFO") $ 244,479.25  
DxNA, LLC DxNA GeneSTAT PCR System $ 244,479.25  
Echelon Biosciences Inc Development of Tools to Study Diseases Associated with Altered Autotaxin and LPA Levels $ 23,265.29 $ 15,177.37
Echelon Biosciences, Inc Sphingolipid Kinase Screening Platforms for the identification of Novel Anti-Cancer Therapie $ 8,860.81 $ 4,815.64
Echelon Biosciences, Inc Assays to detect RAGE-LIGAND INTERACTIONS IN DISEASE DETECTION AND DRUG DISCOVERY   $ 11,634.42
Echelon Biosciences, Inc Broad-spectrum antibiotic development targeting the MEP pathway   $ 15,542.50
Fresh Medical Laboratories Inc. Transthoracic Bioconductance Scanning Device Development as a Lung Cancer Diagnostic $ 136,133.50 $ 108,345.75
Frontier Scientific Inc Biliverdin IX alpha as an anti-inflamatory therapeutic agent $ 3,677.50 $ 4,150.50
Frontier Scientific Inc Frontier Scientific Inc $ 106,321.00 $ 60,284.50
Frost Biologic, Inc Development of WNK kinase inhibitors as anti-cancer drugs $ 27,140.00 $ 217,339.24
Glyco Mira LLC Sulphated Polysaccaride Derivatives $ 104,784.50 $ 139,694.74
Glycosan BioSystems Inc HyStem $ 42,879.50 $ 201,599.75
INTEGRATECH PROTEOMICS LLC DEVELOPMENT OF SMALL MOLECULE HIV INTEGRASE INHIBITOR   $ 169,700.00
JSK Therapeutics, Inc (JSK-T) New Class of Cancer Therapy Drugs $ 52,600.00 $ 37,475.00
LineaGen Inc Identification of Genetic, Proteomic and Serological Biomarkers for COPD $ 23,885.00 $ 16,246.50
LineaGen, Inc Development of Genetic Markers for the Dagnosis of Autism Spectrum Disorders $ 244,479.25  
LineaGen, Inc. Development of Genetic and Serological Markers for the Diagnosis of Multiple Sclerosis $ 204,287.50 $ 40,191.75
Lipocine Inc Oral Sirolimus for Treatment of Progressive Glioblastoma Multiforme (LPCN 1105) $ 160,092.50 $ 84,386.74
Lipocine Inc Oral Testosterone Replacement Therapy (LPCN 1021) $ 244,479.24  
LIPOCINE INC ORAL PROGESTERONE FOR HIGH-RISK PREGNANCY SUPPORT (LPCN 1002) $ 5,242.00 $ 239,237.24
Lipocine Inc. Benzonatate for Opioid Resistant Cough in Advanced Cancer Patients (LPCN 1035) $ 124,945.50 $ 119,533.74
Max International LLC Project Heart-RiboCeine   $ 244,479.25
Max International, LLC Max GlutathioCeine   $ 244,479.25
Myrexis Inc Azixa $ 244,479.25  
Myrexis Inc MPC-9528 $ 244,479.25  
Myrexis Inc MPC-3100 $ 244,479.25  
Myrexis, Inc MPC-4326 $ 244,479.25  
Myrexis, Inc MPI-485520 $ 244,479.25  
Navigen Pharmaceuticals, Inc SecinH3 project $ 244,479.25  
Navigen Pharmaceuticals, Inc Semaphorin 3E - anti platelet project $ 176,636.00 $ 67,843.25
Navigen Pharmaceuticals, Inc. Slit2N to Prevent Cytokine-Induced Vascular Leak $ 244,479.25  
NeuroAdjuvants, Inc. Development of Galanin-Based Therapy for Treatment of Epilepsy $ 210,661.44 $ 33,817.81
NuView Life Sciences, Inc NuVIew Life Sciences Research and Development FXA-18 $ 49,985.30 $ 194,493.94
NuView Life Sciences, Inc NuView Life Sciences Research and Development PCO-Cataract   $ 244,479.24
NuView Life Sciences, Inc NUView Life Sciences Research and Development Breast Cancer biomarker $ 10,362.50 $ 234,116.75
NuView Life Sciences, Inc NuView Life Sciences Research and Development FMAU   $ 244,479.24
NuView Life Sciences, Inc. NuView Life Sciences Research and Development Lymphoma biomarker $ 239,840.73 $ 4,638.51
PPR Group, Inc. PRLX93936 $ 244,479.25  
Q Therapeutics, Inc. Human Glial Progenitor Cells for Treatment  of Amyotropic Lateral Sclerosis $ 174,764.62 $ 69,714.63
Sera Prognostics, Inc. Preterm Birth Serum Biomarker Test $ 74,479.17 $ 143,391.78
Taueret Laboratories Preeclampsia and Preterm Labor Gene Mapping $ 244,479.25  
TK Biotech, Inc TK1 as a Diagnostic, Prognostic and Therapeutic Cancer Marker $ 60,550.00 $ 133,000.00
TransDerm Inc Development of siRNA Therapeutics for Treatment of Skin Disorders $ 244,479.25  
Viropan Inc 30-Day Intravaginal Ring for Prevention of Sexually-Transmitted HPV Infection in Women $ 34,875.00 $ 209,604.25
Vital Access Corporation Vital Access' Venous Windowtm Needle Guide (VWNG) $ 177,017.28 $ 67,461.97
Vital Access Corporation Vital Access - Access Device: a novel minimally-invasive medical device $ 244,479.25  
World Hearts Inc Levacor VAD $ 244,479.25  
ZARS Pharma, Inc. Flexicaine for Treating Post-herpetic Neuralgia $ 221,565.00 $ 22,914.25
ZARS Pharma, Inc. Triamcinolone DuraPeel TM to Treat Hand Dermatitis $ 244,479.25  
Page Last Reviewed or Updated: 26-Mar-2014